The ErbB receptor family: a therapeutic target for cancer
2002 · Trends in Molecular Medicine · 204 citations
https://doi.org/10.1016/s1471-4914(02)02306-7
E
Eric K. Rowinsky
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
477
Papers
41.2K
Citations
89
h-index
299
i10-index
Eric K. Rowinsky is an academic researcher. The author has contributed to research in topics: Cancer Treatment and Pharmacology & Cancer therapeutics and mechanisms & Colorectal Cancer Treatments and Studies. The author has an h-index of 89, co-authored 406 publications.
ORCID: 0000-0002-0848-4826Papers by this author
worksPhase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP.
1998 · Journal of Clinical Oncology · 146 citations
https://doi.org/10.1200/jco.1998.16.9.2964
Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma
2020 · Investigational New Drugs · 91 citations
https://doi.org/10.1007/s10637-020-00915-4
Signal Events: Cell Signal Transduction and Its Inhibition in Cancer
2003 · The Oncologist · 80 citations
https://doi.org/10.1634/theoncologist.8-suppl_3-5
Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity
2004 · Annals of Oncology · 68 citations
https://doi.org/10.1093/annonc/mdh472
Challenges of Developing Therapeutics That Target Signal Transduction in Patients With Gynecologic and Other Malignancies
2003 · Journal of Clinical Oncology · 14 citations
https://doi.org/10.1200/jco.2003.01.146
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat